Expression and Clinical Significance ofα1-antitrypsin in Serum of Patients with Stable Chronic Obstructive Pulmonary Disease Complicated with Bronchiectasis
ZHANG Li, LIU Xuan, LU Shen-dong,et al
Respiration Department, Changshu Hospital Affiliated to Soochow University, First People’s Hospital of Changshu City, Changshu215500, Jiangsu Province, China
Abstract：【Objective】To investigate the level and significance of serum α1-antitrypsin (α1-AT) in patients with chronic obstructive pulmonary disease (COPD) complicated with bronchiectasis.【Methods】From January 2017 to December 2018, 64 stable COPD patients with bronchiectasis (combined group) were selected from the respiratory department of our hospital. In addition, 50 stable COPD patients who were treated in our hospital at the same time were selected as the COPD group and 50 healthy people in our hospital as the control group. The expression level ofα1-AT in serum of three groups was detected. The rs1243166 single nucleotide polymorphism of α 1-AT gene was detected by sequenom method and compared.【Results】There was no significant difference in age, gender, smoking history, drinking history, systolic blood pressure and diastolic blood pressure among the three groups (P>0.05). The levels ofα1-AT in the control group, COPD group and combined group were (1.79±0.56) mg / L, (1.45±0.45) mg / L, (0.81±0.31) mg / L, respectively, which decreased in turn, and there was a significant difference between the two groups (P<0.05). ROC curve showed that the best critical point ofα1-AT level diagnosis of COPD combined with bronchiectasis was 3.21 mg / L. at this time, the sensitivity ofα1-AT level diagnosis of COPD combined with bronchiectasis was 71.5%, the specificity was 79.4%; the area under AUC curve was 0.79. There was significant difference in rs1243166 single nucleotide polymorphism among the three groups (P<0.05). The frequencies of GG and GA genotype in the combined group were significantly higher than those in the COPD group and the control group. Compared with AA, the risk of COPD with bronchiectasis in GG and GA was 1.154 and 1.697.【Conclusion】 Alpha 1-AT level is more sensitive and specific in diagnosing COPD combined with bronchiectasis, and incidence rate ofα1-AT gene rs1243166 GG type and GA type COPD combined with bronchiectasis is high.
[1] Seyama K, Hirai T, Mishima M,et al. A nationwide epidemiological survey of alpha1-antitrypsin deficiency in Japan[J].Respir Investig,2016,54(3):201-206.
[2] Edgar RG, Patel M, Bayliss S, et al. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review[J].Int J Chron Obstruct Pulmon Dis,2017,12:1295-1308.
[3] Turino GM, Ma S, Cantor JO, et al. Biomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease[J].Ann Am Thorac Soc,2016,13(Suppl 4):S336-S340.
[4] 王婧雯,王秋颖,徐建国.慢性阻塞性肺病稳定期合并2型糖尿病患者血清α1-抗胰蛋白酶、中性粒细胞弹力蛋白酶水平[J].中国老年学杂志,2013,33(3):510-511.
[5] 2016 GOLD.COPD 诊断、治疗与预防全球策略(更新版)[J].中国全科医学,2016,19(5):524.
[6] Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence[J].Respir Res,2017,18(1):105.
[7] Jouhadi Z, Odou MF, Zerimech F, et al. Alpha1 antitrypsin deficiency due to an homozygous PI* Null Q0Cairo mutation: Early onset of pulmonary manifestations and variability of clinical expression[J].Respir Med Case Rep,2018,24:58-62.
[8] 钟雪梅,李黎,米热班·热夏提, 等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(2):67-70.
[9] 王林升,张国玉,周孟恩.支气管扩张患者α1-AT的基因多态性和血清α1-AT水平及其临床意义的研究[J].临床肺科杂志,2010,15(10):1414-1416.
[10] 邱洁,张雅囡,陈娟, 等.宁夏地区慢性阻塞性肺疾病血清α1-抗胰蛋白酶检测分析[J].中国现代医学杂志,2012,22(17):58-61.
[11] 宋帅.α1-抗胰蛋白酶最新研究进展[J].国际检验医学杂志,2018,39(11):1356-1360.
[12] Mueller C, Gernoux G, Gruntman AM, et al. 5 year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency[J].Mol Ther,2017,25(6):1387-1394.
[13] Hazari YM, Bashir A, Habib M, et al. Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions[J].Mutat Res,2017,773:14-25.
2020, Vol. 37 
